Sage Therapeutics (SAGE) ~45% Upside Does Not Nearly Reflect Potential Market Opportunity - RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
SAGE Therapeutics (SAGE) 'Hits It Out of the Park' with SAGE-217 Data - Cowen
January 7, 2019 11:56 AM ESTCowen analyst Ritu Baral reiterated an Outperform rating and $207 price target on Sage Therapeutics (NASDAQ: SAGE) after the company reported highly positive top-line data from the Ph3 ROBIN study of SAGE-217 in postpartum depression.
Baral commented, "The trial met primary endpoint with... More
Sage Therapeutics (SAGE) SAGE-217 Ph3 Data 'Very Impressive' - BMO
January 7, 2019 11:52 AM ESTBMO Capital analyst Gary Nachman reiterated an Outperform rating and $203 price target on Sage Therapeutics (NASDAQ: SAGE) after the company reported "very impressive" Ph3 data for SAGE-217 in PPD that demonstrated strong efficacy across the board and an overall good safety... More
Sage Therapeutics (SAGE) PT Raised to $90 at Leerink Partners
January 7, 2019 11:48 AM ESTLeerink Partners analyst Marc Goodman raised the price target on Sage Therapeutics (NASDAQ: SAGE) to $90.00 (from $80.00) while maintaining a Underperform rating.
... MorePre-Open Stock Movers 01/07: (LXFT) (LOXO) (SAGE) Higher; (PCG) (NHTC) (DXC) Lower (more...)
January 7, 2019 9:23 AM ESTToday's Pre-Open Stock Movers
Axsome Therapeutics, Inc. (NASDAQ: AXSM) 189.4% HIGHER; announced that AXS-05, a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the prespecified primary endpoint and significantly improved symptoms of depression in the ASCEND Phase 2 trial in major depressive disorder (MDD). The ASCEND study is a randomized, double-blind, active-controlled, multi-center, U.S. trial, in which 80 adult patients with confirmed moderate to severe MDD were treated either with AXS-05 (45 mg dextromethorphan/105 mg bupropion), or the active comparator bupropion (105 mg), twice daily for 6 weeks.
MYnd Analytics, Inc. (Nasdaq:... More
SAGE Therapeutics (SAGE) Surges on Positive SAGE-217 Phase 3 Data
January 7, 2019 8:14 AM ESTSAGE Therapeutics (NASDAQ: SAGE) is surging 34% in pre-open trade after the company reported positive top-line results from the Phase 3 ROBIN Study.
... MoreSAGE Therapeutics (SAGE) Reports SAGE-217 Meets Primary and Secondary Endpoints in Phase 3 Clinical Trial in Postpartum Depression
January 7, 2019 6:01 AM ESTSage Therapeutics (NASDAQ: SAGE) today reported top-line results from the Phase 3 ROBIN Study. This study evaluated the effect of SAGE-217 30 mg on depressive symptoms in women with postpartum depression (PPD). After two weeks of outpatient treatment, patients treated with SAGE-217 had a statistically significant improvement of 17.8 points in the Hamilton Rating Scale for Depression (HAMD-17) score, compared to 13.6 for placebo (primary endpoint, p=0.0029), with statistically significant reductions in HAMD-17 compared to placebo maintained through the end of the four-week follow-up. Remission was achieved in 45% of patients treated with SAGE-217 for two weeks as... More
